Breast cancer is a common manifestation of an underlying genetic susceptibility to cancer, and 5% to 10% of all breast cancers are associated with a germline mutation in a known risk allele.

This review highlights the significant advances made in the diagnosis and management of penile cancer.

Bladder cancer is predominantly seen in elderly patients. With the aging United States population, the incidence and prevalence of bladder cancer are on the rise, heightening the relevance of this disease as a public health issue.

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates.

Leptomeningeal carcinomatosis (LM) is an infrequent, yet morbid and often fatal complication of non–small cell lung cancer (NSCLC).

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin’s Lymphoma (NHL) and provide a discussion of the clinical evidence that support the updates.

Neoadjuvant chemoradiation (CRT) is standard treatment for stage II–III rectal cancer. Fluoropyrimidine-based CRT prolongs disease-free survival over adjuvant CRT and improves local control over both adjuvant CRT and neoadjuvant radiotherapy alone, but does not prolong overall survival.

Decisions regarding adjuvant chemotherapy for patients with estrogen receptor (ER)–positive HER2-negative lymph node–negative breast cancer have traditionally relied on clinical and pathologic parameters.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, patient surveillanc

Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive lymphoma that confers a poor prognosis with current treatment strategies. Given the rarity of this disease, prospective randomized trials are limited, andthus a standard validated treatment strategy is lacking.